BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Evidence Sheets

Evidence Sheet: Moderna (MRNA)

Moe Alsumidaie by Moe Alsumidaie
November 9, 2026
in Evidence Sheets
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

This is the standing evidence sheet for Moderna (MRNA): the yardsticks BullScope computes from official SEC filings and market prices. It refreshes whenever a new edition of our research is published, and it is impersonal by design, every reader sees the same page. Nothing here is investment advice; it is the evidence, organized.

The price tag: what buyers pay per dollar of profit

As the filed record below shows, Moderna has reported negative GAAP EPS in each of FY2023, FY2024, and FY2025, making a conventional trailing price-to-earnings ratio undefined on a GAAP basis. If and when the company returns to positive earnings, the price-to-earnings multiple implied by the current share price can be compared against the historical median of 4.4 recorded during the profitable FY2021–FY2022 period.

The tape: what the stock itself has done

  • Last price: $254.19 (end-of-day market data as of the edition date · methodology) · 2% below its 52-week high
  • Past 6-month and 12-month return figures are not shown here pending source verification against the named market-data provider; see the edition date and methodology page for data sourcing details.
  • Day-to-day temperament: jumpy (annualized volatility 194%)

The filed record: straight from the annual reports

Fiscal year Revenue Growth Operating margin EPS
FY2021 $18.5B , 72.0% $28.29
FY2022 $19.3B +4.3% 48.9% $20.12
FY2023 $6.8B -64.4% -61.9% $-12.33
FY2024 $3.2B -52.7% -121.9% $-9.28
FY2025 $1.9B -39.9% -158.1% $-7.26

The road ahead: filed results vs published expectations

FY2023A FY2024A FY2025A FY2026E FY2027E FY2028E
Net sales ($B) 6.8 3.2 1.9 2.1 to 2.5 1.5 to 3.5 1.6 to 5.2
Net sales growth (%) -64.2 -52.9 -40.6 10 -29 6
Operating margin (%) -61.8 -121.9 -163.2 -145 to -110 -175 to -60 -135 to -85
Diluted EPS ($) -12.33 -9.28 -7.26 -9.50 to -6.50 -12.00 to -2.50 -11.00 to -7.50

Columns marked A are actual filed results; E columns are the published consensus ranges the current price is being weighed against.

The four gauges: from the latest edition

Can it keep growing?: 18/100 (higher is better)Can it keep growing?18higher is betterCompetition pressure: 72/100 (higher is worse)Competition pressure72higher is worseLegal & political risk: 68/100 (higher is worse)Legal & political risk68higher is worseCost & margin risk: 85/100 (higher is worse)Cost & margin risk85higher is worse
Hover any bar for the reading. Scored 0–100 per BullScope’s published scoring framework; inputs drawn from SEC filings and named datasets as described therein. Green is favorable on every bar.

BullScope coverage of Moderna

  • Moderna Brings Back Operations Chief as Oncology Push Demands Manufacturing Scale
  • Moderna at 28 Times Sales: One Trial Result Is Doing a Lot of Work
  • Moderna raises $2.6 billion in zero-coupon convertibles as revenue collapses, betting oncology turnaround

Read the full report on Moderna in the BullScope Terminal → It opens with this company loaded.

Edition date: 2026-11-09. This page updates when a new edition is published. Sources: SEC EDGAR filings, Nasdaq prices; computed by BullScope’s published methodology.

BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read Moderna’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Evidence Sheet: Palantir Technologies (PLTR)

by Moe Alsumidaie
November 6, 2026
0

The standing BullScope yardsticks for Palantir Technologies, computed from official filings and refreshed with each new edition.

Read moreDetails

Evidence Sheet: Honeywell International (HON)

by Moe Alsumidaie
October 26, 2026
0

The standing BullScope yardsticks for Honeywell International, computed from official filings and refreshed with each new edition.

Read moreDetails

Evidence Sheet: Chevron (CVX)

by Moe Alsumidaie
November 6, 2026
0

The standing BullScope yardsticks for Chevron, computed from official filings and refreshed with each new edition.

Read moreDetails

Evidence Sheet: General Electric (GE)

by Moe Alsumidaie
October 22, 2026
0

The standing BullScope yardsticks for General Electric, computed from official filings and refreshed with each new edition.

Read moreDetails

Evidence Sheet: American Express (AXP)

by Moe Alsumidaie
October 26, 2026
0

The standing BullScope yardsticks for American Express, computed from official filings and refreshed with each new edition.

Read moreDetails
Next Post

UnitedHealth's Numbers Are Healing Faster Than Its Stock Admits

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

CorMedix: The Company That Went From Zero to Profitable, and the Filing That Could Change the Equation Again

October 28, 2026

Target’s Revenue Has Shrunk for Three Straight Years. Its Stock Just Hit a 52-Week High.

August 14, 2026

Regeneron secures $1 billion upfront and profit-share deal with Sanofi on four new antibodies

October 7, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.